Screener
Zura Bio Limited ZURA Q3 2026 earnings
Reported October 27, 2026 · Before market open
EPS-$0.20Beat by $0.00
EPS estimate-$0.20
“We continue to believe deeply in tibulizumab's potential to address complex immune biology and unmet needs across indications, including in PMR, where we will be starting the NEXUS-PMR study by end of year. With cash runway sufficient to deliver results from all three studies, Zura is in a great position to deliver on tibulizumab's unique potential.”
Next report
Date not yet announcedVersus estimates
Diluted EPS
FAQ
- When did Zura Bio Limited report Q3 2026 earnings?
- Zura Bio Limited (ZURA) reported Q3 2026 earnings on October 27, 2026 before market open.
- What were Zura Bio Limited's Q3 2026 revenue and EPS?
- Zura Bio Limited reported eps of $-0.20 for Q3 2026.
- Did Zura Bio Limited beat estimates in Q3 2026?
- EPS beat the consensus estimate of $-0.20 by $0.00.
- How did Zura Bio Limited's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 4.8% from $-0.21.
- Where can I find Zura Bio Limited's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001855644-26-000012) and the 10-Q periodic report (0001855644-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.
